Episode Details

Claire Mazumdar, CEO of Bicara Therapeutics, sold 8,234 shares, totaling $154,000, following a preset trading plan. This represents less than 2.5% of her direct ownership, maintaining her significant stake in the company. Bicara, focused on bifunctional antibody treatments for solid tumors, has a market value of $1.04 billion, up 45% in the past year. Their lead drug has breakthrough therapy status, with trial results expected mid-2027.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/cb1533cffbafa181